BAM15

Mitochondrial uncoupler

BAM15 (Mitochondrial uncoupler) is a metabolic & fat loss research compound. Protonophore that mildly uncouples oxidative phosphorylation, so you burn more energy as heat — fat loss without appetite games.

How BAM15 works

Protonophore that mildly uncouples oxidative phosphorylation, so you burn more energy as heat — fat loss without appetite games.

Proposed benefits

Mild mitochondrial uncoupling for fat loss without appetite changes (rodent-stage).

Where to get BAM15

BAM15 is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.

The evidence for BAM15

Graded by what exists behind each claim.

Human clinical evidence

• No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.

📊 Correlative data

• Limited research-market use. The relevant history is not this compound's — it is DNP's: a mitochondrial uncoupler sold for weight loss in the 1930s that killed people through uncontrolled hyperthermia and is still killing people today. Every uncoupler is read against that record.
• Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.

🧪 How the mechanism reads

• A mitochondrial uncoupler. It carries protons across the inner mitochondrial membrane, dissipating the gradient that drives ATP synthesis — so the cell burns substrate and releases the energy as heat instead of capturing it.
• The specific design claim is a much wider safety window than DNP. BAM15 is reported to be selective for the mitochondrial inner membrane and not to depolarize the plasma membrane, which in rodent work allowed fat loss without the hyperthermia and lethality DNP produces.
• A wider window is not a safe window. Uncoupling has no antidote, the dose-response for heat production is steep, and 'safer than the compound that kills people' is a comparison, not a clearance. Nobody has established the human margin.

Why an empty tier is not a verdict → · What community dosing logs are worth →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What BAM15 actually does

An uncoupler is a molecule that carries a proton back across the inner mitochondrial membrane without letting it pass through ATP synthase. The respiratory chain keeps pumping, the proton keeps coming back the short way, and the energy that would have become ATP leaves as heat. Substrate oxidation therefore speeds up while ATP output falls. That is the whole mechanism, and it is the same mechanism as 2,4-dinitrophenol.

BAM15 is (2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine Kenwood 2014. Direct electrical measurement on planar lipid bilayers confirms it behaves as a classical anionic protonophore, with proton conductance close to that of CCCP, and its activity falls when the membrane dipole potential is reduced — which is what a true protonophore is supposed to do Firsov 2021.

The selling point is one specific negative result. FCCP and DNP also depolarize the plasma membrane, which is where their cytotoxicity and their narrow therapeutic index come from. BAM15 was found in a screen designed to eliminate exactly that, and against FCCP at equal potency it drove a higher maximum respiration rate with less cytotoxicity Kenwood 2014.

Two numbers define the window, and they are the only two that exist. For stimulating cellular oxygen consumption, BAM15's EC50 is 1.4 µM against DNP's 10.1 µM — about seven-fold more potent — and DNP escalated above 30 µM stops stimulating respiration and starts inhibiting it, where BAM15 keeps working across a wider range Alexopoulos 2020. That difference in curve shape, not the potency, is the actual argument.

Where the clean story frays. In isolated rat liver mitochondria, BAM15's uncoupling was partially reversed by carboxyatractyloside, an inhibitor of the adenine nucleotide translocase — so part of the effect runs through a transport protein rather than through free protonophoresis. And in molluscan neurons BAM15 did depolarize the plasma membrane and suppress electrical activity, more slowly than CCCP but it did it Firsov 2021. "Does not depolarize the plasma membrane" is a result in one preparation, not a property of the molecule everywhere. Downstream, sustained AMPK activation is the signaling consequence reported in cells Axelrod 2020 — the expected answer to a falling ATP:AMP ratio.

Cell, rodent, human — and where it stops

Step one, in cells. A small-molecule library screen, then validation in cultured cells: higher maximal mitochondrial respiration than FCCP at equal potency, less cytotoxicity, no plasma-membrane depolarization Kenwood 2014.

Step two, an acute injury model in mice. Still Kenwood 2014: BAM15 dose-dependently protected mice from acute renal ischemia-reperfusion injury. That is an in vivo demonstration that the compound reaches mitochondria in a living animal and does something measurable.

Step three, the obesity work, and here is the dosing detail nobody quotes. Alexopoulos 2020 gave BAM15 to mice by oral gavage at 10, 50 and 100 mg/kg for indirect calorimetry, and mixed it into a Western diet at 0.05%, 0.10% and 0.15% w/w for the chronic experiments, with fat pads dissected at 8 days and glucose tolerance tested at 7 days. Body fat mass fell with no change in food intake, lean mass, body temperature or the biochemical markers measured; hepatic fat fell; hyperinsulinemic-euglycemic clamps showed improved insulin sensitivity in multiple tissues.

Step four, an independent group, a different design. Axelrod 2020 treated C57BL/6J mice and found them resistant to weight gain, with improved body composition and glycemic control independent of weight loss, an effect the authors attribute to drug distribution into lipid-rich tissues. Two labs, same direction.

Step five, in humans: nothing. No trial, no case series, no published human pharmacokinetic study. The 2023 review that summarizes the field lists obesity, diabetes, fatty liver disease, sepsis and cardiovascular disease as potential indications and then names the outstanding problems as high lipophilicity and the need for alternative delivery methods Xiong 2023. Those are formulation problems, which is what a compound has instead of clinical data when it has never been in a person.

The obstacle, stated exactly. Every rodent result above sits at a measured plasma concentration of 5–10 µM, sustained by feeding Alexopoulos 2020. Nobody knows what oral dose produces 5–10 µM in a human, because no human has ever had the level drawn. Translation here is not blocked by biology — proton leak is proton leak in every eukaryote — it is blocked by the complete absence of a human exposure–response curve for a drug class that has killed people when the exposure was wrong.

BAM15 pharmacokinetics — how much of it actually gets in

Route: oral, and the mouse numbers are unusually complete. At a 10 mg/kg oral dose in mice, BAM15 was 67% orally bioavailable, with a mean Cmax of 8.2 µM and a half-life of 1.7 hours; it distributed primarily to the liver and cleared from tissues over roughly 4 hours Alexopoulos 2020. Fed at 0.1% w/w it held plasma between 5 and 10 µM. A 1.7-hour half-life with continuous dietary exposure is why the mouse studies fed the drug rather than dosing it once a day.

What degrades it. Not published. There is no CYP assignment, no hepatic or renal clearance fraction, and no metabolite identification for BAM15 in any species — the liver distribution and rapid tissue clearance above are the only handles that exist. That absence is itself a finding: interaction risk with anything else you are taking cannot be reasoned about at all.

The oral barrier. 67% oral bioavailability in a mouse is high for a compound the field describes as highly lipophilic, and lipophilicity is exactly the property the 2023 review names as the obstacle to further development Xiong 2023. High first-pass extraction into the liver is consistent with the tissue distribution reported. There is no injectable BAM15 formulation with published pharmacokinetics, so a subcutaneous injection of it has no exposure profile anyone can quote.

The arithmetic, done out loud, because it is the most useful thing on this page. A 30 g mouse eats about 3.5 g of chow a day, so 0.1% w/w is roughly 3.5 mg/day, or about 115 mg/kg/day. Converting to a human-equivalent dose by the standard body-surface-area factors (mouse 3, human 37) gives about 9 mg/kg, which is roughly 650 mg a day for a 70 kg adult. Set that against the 50–150 mg this site records and the vault dose is four to thirteen times lower than the scaled animal dose. That is a calculation, not a measurement, and it is offered as one — but it means the honest description of a 100 mg capsule is not "a smaller dose of a proven effect" but "an exposure nobody has shown does anything, in either direction."

What would have to be true, and how you would know it was not

Four predictions. The fourth is the one that argues against taking it at all, and the third is the one that would tell you the window has been crossed.

1. Metabolic markers should move before the scale does. Axelrod 2020 found improved glycemic control independent of weight loss. So draw fasting insulin and HbA1c at baseline and at 12 weeks. The falsifiable claim is that if this compound is uncoupling at your dose, insulin should fall even in somebody whose weight has not changed. If both markers are flat and weight is flat, the simplest explanation is that the exposure is below the level anything happened at in mice.

2. The liver is where it goes, so the liver is what you watch. Primary distribution was hepatic Alexopoulos 2020. A CMP and a GGT at baseline and at 8–12 weeks are the minimum. The mouse data predict hepatic fat should fall, not that enzymes should rise — so a transaminase rise is the mechanism failing, not working.

3. Body temperature should NOT rise, and this is the prediction that decides whether to continue. In mice, oral doses up to 200 mg/kg produced no change in body temperature, and the chronic feeding studies reported none either Alexopoulos 2020. Take a resting oral temperature at the same time each morning for two weeks. A sustained rise, sweating, or a resting heart rate climbing 10–15 beats above your own baseline is the 2,4-dinitrophenol toxidrome Grundlingh 2011 and it means stop, not reduce.

4. The prediction that cuts against it: a thyroid panel should be completely unmoved, and if it is not, the product is not what it says. Chemical uncoupling and thyrotoxicosis produce a similar felt experience — warmth, appetite, a racing pulse — by completely different routes, and the cheapest way to catch a contaminated or mislabeled capsule is to show that TSH and free T4 have not changed. A suppressed TSH on a compound with no thyroid mechanism means you are taking something else.

What nobody has tested yet

No human has ever had a plasma BAM15 level drawn. This is the single most valuable missing measurement in the whole file. Every rodent result is anchored to 5–10 µM Alexopoulos 2020, and until somebody runs an LC-MS/MS assay on a few people at a known oral dose, no rodent dose in the literature can be converted into a human one. It is a single-timepoint blood draw and a validated assay, and it would turn every number on this page from arithmetic into evidence.

Nobody has put a person taking it on a metabolic cart. The entire claim is that energy expenditure rises while body temperature does not. Indirect calorimetry measures the first half in about an hour and a tympanic thermometer measures the second; the mouse experiment that produced the claim is directly repeatable in a human in a morning Alexopoulos 2020.

Nobody has asked whether the adenine nucleotide translocase matters in vivo. Firsov 2021 showed part of BAM15's uncoupling in isolated mitochondria is carboxyatractyloside-sensitive. If a transport protein carries some of the effect, then ANT expression differs between tissues and people, and the dose-response would too. The experiment is a comparison of BAM15's effect on respiration in mitochondria from ANT-deficient against wild-type tissue, and it has not been done.

Nobody has established the top of the curve in any species. The mouse work found doses that work and reported transient lethargy at the highest ones. It did not find the dose that harms, which means the therapeutic ratio — the number the entire safety argument for this molecule rests on — has never actually been measured.

BAM15 — its own safety story, not its class's

Start with the body count, because it is the reason this compound exists. 2,4-dinitrophenol acts by the same mechanism and has 62 published deaths in the medical literature, killing through a stereotyped toxidrome of hyperthermia, tachycardia, diaphoresis and tachypnoea Grundlingh 2011. Nothing about BAM15 changes the physics of uncoupling. What is claimed is a wider gap between the dose that works and the dose that kills.

Here is that gap, in full, as published. BAM15 stimulates oxygen consumption with an EC50 of 1.4 µM against DNP's 10.1 µM; DNP above 30 µM switches from stimulating respiration to inhibiting it while BAM15 does not; oral doses up to 200 mg/kg in mice produced no body-temperature change, with transient lethargy at 150–200 mg/kg Alexopoulos 2020. That is the complete safety dataset. There is no LD50 comparison, no repeat-dose toxicology study in a second species, no maximum tolerated dose in a human, and therefore no therapeutic index — only a potency ratio in a dish and an absence of fever in a mouse.

The missing alarm, which is the argument this page exists to make. With DNP the toxidrome announces itself as heat, and that is the sign that tells somebody to stop. In mice, BAM15 raised metabolic rate without raising temperature. If that carries over to people, then the early-warning signal every DNP user relies on is absent by design — which is a real advantage if the window is genuinely wide and a genuinely worse situation if it is not. Nobody knows which, because nobody has found the top of the curve in any species.

Two smaller things that are its own, not the class's. First, the mitochondrial selectivity is relative: in molluscan neurons BAM15 depolarized the plasma membrane and suppressed electrical activity, just more slowly than CCCP Firsov 2021. Second, there is no pharmacopoeial monograph and no approved product, so identity and purity rest entirely on a vendor certificate for a molecule whose whole safety case is a concentration–response curve. Getting the concentration wrong is the failure mode.

Sources read for this page

• Kenwood BM, Weaver JL, Bajwa A, Poon IK, Byrne FL, Murrow BA, Calderone JA, Huang L, Divakaruni AS, Tomsig JL, Okabe K, Lo RH, Cameron Coleman G, Columbus L, Yan Z, Saucerman JJ, Smith JS, Holmes JW, Lynch KR, Ravichandran KS, Uchiyama S, Santos WL, Rogers GW, Okusa MD, Bayliss DA, Hoehn KL. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane.. Mol Metab 2014 · PMID 24634817
• Alexopoulos SJ, Chen SY, Brandon AE, Salamoun JM, Byrne FL, Garcia CJ, Beretta M, Olzomer EM, Shah DP, Philp AM, Hargett SR, Lawrence RT, Lee B, Sligar J, Carrive P, Tucker SP, Philp A, Lackner C, Turner N, Cooney GJ, Santos WL, Hoehn KL. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice.. Nat Commun 2020 · PMID 32409697
• Axelrod CL, King WT, Davuluri G, Noland RC, Hall J, Hull M, Dantas WS, Zunica ER, Alexopoulos SJ, Hoehn KL, Langohr I, Stadler K, Doyle H, Schmidt E, Nieuwoudt S, Fitzgerald K, Pergola K, Fujioka H, Mey JT, Fealy C, Mulya A, Beyl R, Hoppel CL, Kirwan JP. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control.. EMBO Mol Med 2020 · PMID 32519812
• Firsov AM, Popova LB, Khailova LS, Nazarov PA, Kotova EA, Antonenko YN. Protonophoric action of BAM15 on planar bilayers, liposomes, mitochondria, bacteria and neurons.. Bioelectrochemistry 2021 · PMID 32971482
• Xiong G, Zhang K, Ma Y, Song Y, Zhang W, Qi T, Qiu H, Shi J, Kan C, Zhang J, Sun X. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases.. Front Endocrinol (Lausanne) 2023 · PMID 37900126
• Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM. 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death.. J Med Toxicol 2011 · PMID 21739343

BAM15 — safety, predicted from mechanism

BAM15 — interference & stacking

Bloodwork to run alongside BAM15

Baseline first, then again at 8–12 weeks.

The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.

Check results you already have → · All 103 markers A–Z

BAM15 — frequently asked questions

BAM15 inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What BAM15 is used for

BAM15 appears under 1 goal in the goal router.

Related Metabolic & Fat Loss compounds

← Explore the full Protocol Vault

↑ Back to on this page